Nostaeva, A., Beuriot, J., Jerusalem, G., Azarzar, S., Donneau, A.-F., Rahmouni, S., The Ensemble Team, Louis, E., Pétré, B., Vieujean, S., Durieux, R. (Other coll.), Firket, P. (Other coll.), Gendebien, Z. (Other coll.), Georges, M. (Other coll.), Gillet, P. (Other coll.), Gilon, M. (Other coll.), Gosseries, O. (Other coll.), Guiot, J. (Other coll.), JACQUINET, A. (Other coll.), ... Daenen, G. (Other coll.). (in press). Patients’ and specialist physicians’ perspectives on the use of polygenic risk scores in clinical practice: a cross-sectional study. BMC Medical Genomics. doi:10.1186/s12920-026-02454-y |
Wick, M., Streel, S., Gizzi, M., Seront, E., Sacre, A., Seidel, L., & Gennigens, C. (November 2025). Lymph node metastases and survival outcomes in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based therapies – A retrospective multicenter study. European Urology Open Science, 81, 297. doi:10.1016/s2666-1683(25)01672-6 |
PETIT, E., Jerusalem, G., Denis, C., Wick, M., Freres, P., Gennigens, C., & Sautois, B. (September 2025). Les inhibiteurs de PARP (poly-ADP-ribose polymérase) : des nouveaux venus dans la prise en charge des cancers de la prostate. Revue Médicale de Liège, 80 (9), 592 - 597. |
Wick, M., Denis, C., Freres, P., Sautois, B., Waltregny, D., & Gennigens, C. (May 2025). Prise en charge du cancer du rein en 2025. Revue Médicale de Liège, 80 (5-6), 323 - 329. |
Wick, M., Sautois, B., Freres, P., Denis, C., Seidel, L., Waltregny, D., & Gennigens, C. (2024). Metastatic reanl cell carcinoma : monocentric retrospective data on first-line treatment. Belgian Journal of Medical Oncology. |